Is IceCure Medical Ltd. (ICCM) Halal?

NASDAQ Healthcare Israel $27M
✓ HALAL
Confidence: 95/100
IceCure Medical Ltd. (ICCM) is Halal under 3 of 5 Shariah screening standards, including AAOIFI Standard 21. With a debt ratio of just 1.1% against the AAOIFI threshold of 30%, IceCure Medical Ltd. comfortably passes the key financial ratio tests. The company operates in the Healthcare sector (Medical Devices), which is not a prohibited industry under Islamic finance principles.

Shariah Screening — 5 Standards

Based on financial data from December 2025

Standard Debt Ratio Cash Ratio Receivables Income Status
AAOIFI 1.1%
/ 30%
17.4%
/ 30%
0.9%
/ 30%
0.0%
/ 5%
✓ HALAL
DJIM 1.1%
/ 33%
17.4%
/ 33%
0.9%
/ 33%
0.0%
/ 5%
✓ HALAL
MSCI 3.6%
/ 33%
60.1%
/ 33%
3.3%
/ 33%
0.0%
/ 5%
✗ NOT HALAL
S&P 1.1%
/ 33%
17.4%
/ 33%
0.9%
/ 33%
0.0%
/ 5%
✓ HALAL
FTSE 3.6%
/ 33%
60.1%
/ 33%
3.3%
/ 50%
0.0%
/ 5%
✗ NOT HALAL

Financial Highlights

EPS
$-0.24
P/B Ratio
3.0
EV/EBITDA
-1.3
EV: $19M
Revenue
$3M
Growth: 46.2%
Beta
2.3
High volatility
Current Ratio
2.6

Profitability

Gross Margin 36.3%
Operating Margin -329.6%
Net Margin 0.0%
Return on Equity (ROE) -188.8%
Return on Assets (ROA) -71.3%

Cash Flow & Balance Sheet

Operating Cash Flow-$15M
Free Cash Flow-$15M
Total Debt$217,000
Debt-to-Equity2.4
Current Ratio2.6
Total Assets$14M

Price & Trading

Last Close$0.39
50-Day MA$0.61
200-Day MA$0.80
Avg Volume287K
Beta2.3
52-Week Range
$0.37
$1.40

About IceCure Medical Ltd. (ICCM)

CEO
Mr. Eyal Shamir
Employees
67
Sector
Healthcare
Industry
Medical Devices
Country
Israel
Exchange
NASDAQ
Market Cap
$27M
Currency
USD

IceCure Medical Ltd, a commercial-stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors in the United States, Japan, India, China, Israel, and internationally. The company offers the ProSense system, a single probe cryoablation system for the treatment of malignant breast tumors, as well as its associated disposables, including CryoProbes needles, and guiding needles/introducers; and IceSense3 system for ablation indications in urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MSense, a multi probe system for the treatment of multiple and larger tumors. The company serves hospitals, interventional radiological centers, ambulatory centers, and private clinics. IceCure Medical Ltd was incorporated in 2006 and is headquartered in Caesarea, Israel.

Related Halal Stocks in Healthcare

Frequently Asked Questions

Is IceCure Medical Ltd. (ICCM) halal to invest in?

Based on our screening using AAOIFI Standard 21 (the strictest methodology), IceCure Medical Ltd. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.

What is IceCure Medical Ltd.'s debt ratio?

IceCure Medical Ltd.'s debt ratio is 1.1% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 3.6%.

What are IceCure Medical Ltd.'s key financial metrics?

IceCure Medical Ltd. has a market capitalization of $27M, and revenue of $3M. Return on equity stands at -188.8%.

How often is the screening data updated?

Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.

Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.